FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00066638 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

NIH

Sponsor class

Conditions

DS Stage II Plasma Cell Myeloma
DS Stage III Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions

DRUG: Romidepsin
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)